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ABSTRACT 
 
Introduction: There exists a wide range of variation in the prices of drugs marketed in India and other 
countries of the world. Very few studies have been conducted to reveal such price variations in the open 
market. Aim & Objectives: To evaluate the cost of oral anti-diabetics of different generic classes and 
different brand names of one compound, To evaluate the difference in cost of different brands for the 
same active drug by calculating percentage variation of cost. Methods:  Cost of a particular drug being 
manufactured by different companies, in the same strength, number and dosage form was compared. The 
difference  in  the  maximum  and  minimum  price  of  the  same  drug  manufactured  by  different 
pharmaceutical companies and the percentage variation in price was calculated. Results:  In Single drug 
therapy, among  sulfonylurea group  of  drugs,  Glimepiride  (1 mg) shows maximum price  variation of 
655.38%, while Glipizide (10mg) shows variation of 38.88%. In Biguanides & Thizolidinediones groups 
of drugs, Metformin (500 mg) & Pioglitazone (15 mg) show maximum price variation of 308.33% & 
542% respectively. In  α-glucosidases inhibitor group of drugs, Miglitol shows maximum price variation 
of  135.50  %.  In  combination  therapies,  Glipizide  &  Metformin  combination  shows  the  maximum 
variation up to 399.04 %. Conclusion:  The average percentage price variation of different brands of the 
same drug manufactured in India is very wide and the appraisal and management of marketing drugs 
should  be  directed  toward  maximizing  the benefits of  therapy and minimizing  negative personal and 
economic consequences. 
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INTRODUCTION 
 
In the developing countries the cost of drugs is a 
major concern to both physician and patient; yet 
there  are  few  data  on  prescribing  patterns  and 
expenditure
1. Cost of drugs is an important factor 
influencing  compliance  with  treatment
2. 
  In  the 
context  of  pharmaceutical  and  other  health 
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products,  differential  pricing  (also  called  tiered 
pricing) is the adaptation of product prices to the 
purchasing  power  of  consumers  in  different 
geographical  or  socioeconomic  segments. 
Differential  pricing  could  potentially  be  a  very 
effective  strategy to improve access to essential 
medicines  in  low  and  middle-income  countries 
where  most  patients  pay  for  medicines  out-of-
pocket  and  therefore  cannot  afford  the  prices 
compared to high income markets. 
3    
Diabetes is the most common non communicable 
disease  worldwide.  The  International  Diabetes 
Federation  (IDF)  estimates  the  total  number  of 
diabetic  subjects  to  be  around  40.9  million  in 
India and this is further set to rise to 69.9 million 
by the year 2025.
4,5 Diabetes is a chronic disorder. 
It  requires  lifelong  treatment.  So  the  cost  of 
antidiabetic drug is the major deciding factor for 
the  patients’  compliance.  Selection  of  oral 
antihyperglycaemic  agents  as  first-line  drug  or 
combined  therapy  should  be  based  on  both  the 
pharmacological  properties  of  the  compounds 
(efficacy  and  safety  profile)  and  the  clinical 
characteristics  of  the  patient  (stage  of  disease, 
body weight, etc.) 
6. There exists a wide range of 
variation in the prices of drugs marketed in India 
and other countries of the world. 
In the Indian market various antidiabetic drugs of 
various  brands  are  available.  This  creates  a  lot 
problem  with  physician  to  decide  the  drug  of 
choice  for  individual  patients.    Also  in  the 
literature  very  less  studies  are  available  which 
compare  the  cost  of  drugs  of  different  brands. 
Regarding  oral  hypoglycemic  agents,  with  the 
best of our knowledge no study is available which 
compares  the  cost  of  drugs  of  different  brands.  
So,  we  decided  to  carry  out  the  study  which 
compares  prices  of  different  oral  anti-diabetic 
drugs.  
Aim: To evaluate the cost of oral anti-diabetics of 
different brand names of one compound and the 
difference in cost of different brands of the same 
active drug by calculating percentage variation of 
cost. 
Objectives  This  Pharmacoeconomic  study  is 
designed with the main objectives of,  
1.  To find different anti-diabetics available either 
singly or in combination and the No. of the 
brands available for each.  
2.  To evaluate the cost of oral anti-diabetics of 
different  generic  classes  and  different  brand 
names of one compound. 
3.  To evaluate the difference in cost of different 
brands of the same active drug by calculating 
percentage variation of cost. 
 
MATERIALS AND METHODS 
CIMS  (current  index  of  medical  stores)  &  IDR 
(Indian drug review) [2011 issues] were reviewed 
for the prices of drugs used in the management of 
diabetes mellitus. 
1.  The  retail  cost  of  a  particular  drug  being 
manufactured by different companies, in  the 
same strength, number and dosage form was 
compared. 
2.  The difference in the maximum and minimum 
price  of  the  same  drug  manufactured  by 
different  pharmaceutical  companies  was 
calculated. 
3.  The  percentage  variation  in  price  was 
calculated. 
4.  The  drugs  being  manufactured  by  only  one 
company or being manufactured by different 
companies  however,  in  different  strengths 
were excluded. 
The percentage variation in price was calculated 
using the following formula 
2 
  
=
                               −                                 
                               
 100 
The  drugs  were  classified  into  five  categories 
depending on the percentage (%) range of price 
variation. These were as follows 
1)  0-25%  2)  25.1-50%,  3)  50.1-75%,  4)  75.1-
100% and 5) more than 100% Findings of our 
observational  study  were  expressed  as 
absolute numbers as well as percentage. 
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RESULTS 
 
The prices on a total of 20 drugs (11 single and 9 
combination  preparations),  available  in  54 
different  formulations  were  analyzed.  These  54 
formulations  are  manufactured  by  different 
pharmaceutical companies.  
Single  drug  therapy:  In  single  drug  therapy, 
Table  1  shows  the  price  variation  between  a 
sulfonylurea  group  of  drugs.  In  this  group, 
Glimepiride  (1  mg)  shows  maximum  price 
variation  of  655.38%,  while  Glipizide  (10mg) 
shows variation of 38.88%. 
Table  2  shows  price  variation  in  Biguanides 
(Metformin) & Thizolidinediones (Pioglitazones) 
groups of drugs. In these groups, Metformin (500 
mg) & Pioglitazone (15 mg) show maximum price 
variation of 308.33% & 542% respectively. Table 
3  shows  the  price  variation  between  α-
glucosidases  inhibitor  group  of  drugs.  In  this 
group, Miglitol shows maximum price  variation 
of 135.50 %.  Table 4 shows the price variation 
between  Meglitinides  group  of  drugs.  In  this 
group,  Rapaglinide  (0.5  mg)  shows  maximum 
price variation of 90.95 % 
Combination  therapy:In  Combination  therapy, 
total  7  combination  therapies  were  analysed.  In 
this, Glipizide  & Metformin combination shows 
the maximum variation up to 399.04 %. Table V 
shows price variation in combination drug therapy 
 
Table:1. The price varies between a sulfonylurea group of drugs. 
 
Drug  Formulations  Doses 
(mg) 
Manufacturing 
companies 
Min. 
Price (Rs) 
Max. Price 
(Rs) 
% price 
variation 
Glibenclamide  2  2.5   8  2.6  6.05  132.69 
5   9  3.6  9.15  154.16 
Gliclazide  4  30   12  19  64.9  241.57 
40   17  14  27.5  96.43 
60   10  35  99.6  184.57 
80   39  19.5  70.5  261.54 
Glimepiride  4  1   53  8.36  63.15  655.38 
2   53  12.54  117.4  836.2 
3   12  45  125  177.7 
4   20  18.8  103.4  450 
Glipizide  3  2.5   6  2.93  9.35  219.11 
5   14  4.74  13.03  174.89 
10   5  18  25  38.88 
 
Table no. II: Price variation in Biguanides & Thizolidinediones groups of drugs. 
 
Drug  Formulations  Doses 
(mg) 
Manufacturing 
companies 
Min. Price 
(Rs) 
Max. Price 
(Rs) 
% price 
variation 
Metformin  4  250  7  4.6  9  95.65 
500  48  6  24.50  308.33 
850  18  10  36  260 
1000  34  14  41.4  195.71 
Pioglitazone  2  15  40  10  64.20  542 
30  40  18  98.20  445.55 
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Table:3.  Price variation among α-glucosidases inhibitor group of drugs. 
 
Drug  Formulations  Doses 
(mg) 
Manufacturing 
companies 
Min. Price 
(Rs) 
Max. Price 
(Rs) 
% price 
variation 
Acarbose  2 
25  11  32  55  71.87 
50  9  62  89  43.55 
Miglitol  2 
25  8  50  65.82  31.64 
50  14  50.3  118.47  135.50 
Voglibose  2 
0.2  12  36  64  78.05 
0.3  9  54  84  56.74 
 
Table:4.  Price varies between Meglitinides group of drugs 
Drug  Formulations  Doses 
(mg) 
Manufacturing 
companies 
Min. Price 
(Rs) 
Max. Price 
(Rs) 
% price 
variation 
Nateglinide  2  60  4  30  45  50 
120  4  50  70  40 
Repaglinide  3  0.5  6  19.90  38  90.95 
1  4  39  62  58.97 
2  4  75  98  30.66 
 
Table: 5. Price varies among combination therapy 
 
Drugs  Formulation  Doses 
(mg) 
Manufacturin
g companies 
Min. price 
(Rs) 
Max. price 
(Rs) 
% price 
variation 
Glibenclamide 
+ Metformin 
3  2.5 + 400  8  8.15  19  133.33 
2.5 + 500  2  16  26  62.50 
5 + 500  19  12  29.9  149.16 
Glicazide  
+ Metformin 
5  80 + 500  43  18.10  78.25  332.32 
60 + 500  5  39.25  68.50  74.52 
40 + 400  3  28.3  29  2.47 
40 + 500  3  35  60  71.43 
30 + 500  3  32  59  84.37 
Glimepiride + 
Metformin 
5  1+ 500  50  18  69  283.33 
2 + 500  53  26  120.4  362.07 
1 + 1000  2  38  41.75  9.86 
2 + 1000  4  51.8  60  15.83 
2 + 850  2  65  73  12.3 
Glipizide + 
Metformin 
2  5 + 500  11  6.72  14  108.33 
2.5 + 400  3  5.36  26.25  399.04 
Pioglitazone + 
Glimepiride 
3  15 + 1  12  17.1  59.3  246.78 
15 + 2  15  41.9  70  67.06 
30 + 2  2  69  80  15.94 
Pioglitazone + 
Metformin 
2  15 + 500  34  19  70.6  271.57 
30 + 500  21  32.40  86  165.43 
Pioglitazone + 
Metformin + 
Glimepiride 
2  15 + 500 +1  12  44  80  81.81 
15 + 500 +2  15  54  128  137.03 
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Relationship between percent price variation & no. of Manufacturing Companies: 
When we draw a graph showing relationship between manufacturing companies and % price variation, it 
was noted that there is a linear relationship in between these two variables. As the no. of manufacturing 
companies increases, the percent price variation also increases. (As shown in figure no. 1) 
 
 
 
Figure  1:  Graph  showing  relationship  between  percent  variation  &  No.  of  manufacturing 
companies.   
 
DISCUSSION 
 
The Indian market has over 100,000 formulations 
and  there  is  no  system  of  registration  of 
medicines
2.  The  drugs  are  mainly  sold  under 
brand names
7.  
A study in the United States found drug prices to 
be  high  and  that  price  discrimination  occurred 
across  the  industry
7.  But  very  less  studies  are 
available in our scenarios which compare the cost 
of drugs of different brands. Therefore we decided 
to carry out the study which compares the cost of 
different  brands  of  drug  of  most  common 
disorder.  
The drug prices available in CIIMS & IDR were 
compared, as they are readily available source of 
drug information and are updated regularly. Drugs 
used in the management of diabetes mellitus were 
selected  as  it  is  one  of  the  major  causes  of 
morbidity and mortality & the treatment requires 
continuous prescription drug use.  
It is observed from our results that there is a wide 
(up  to  836.20%)  variation  in  prices  of  drugs 
manufactured  by  different  pharmaceutical 
companies.  The  reasons  for  this  price  variation 
could be as follows
8-14:  
1.  The  existing  market  structure  of  the 
pharmaceutical industry 
2.  Asymmetry  of  information  or  imperfect 
information 
3. Industry costs   
4. Government regulations and pricing policies 
From our study it is also clear that, price variation 
was directly related to the number of companies 
manufacturing  a  particular  drug.  So  it  can  be 
concluded  that  the  price  variation  increases 
because of the increase in competition among the 
manufacturing companies. 
Pharmacists do  not dispense  the  same brand  as 
prescribed by the doctor and  try  to  substitute it 
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with other alternatives, quoting the reason of non 
availability. This is often done with vested interest 
for economic gains as some brands have a higher 
profit margin. 
It  is  felt  that  physicians  could  provide  better 
services and reduce costs of drugs if information 
about drug prices  was readily  available. Studies 
have  shown  that  providing  a  manual  of 
comparative  drug  prices  annotated  with 
prescribing  advice  to  physicians  reduced  their 
patients’ drug expense
15. 
Due to the long term treatment duration, diabetes 
patients usually have higher than average monthly 
out-of-pocket  expenses  and  high  out-of-pocket 
expenses  can  be  a  barrier  to  adherence  to 
prescription drug regimens. Many chronically ill 
adults  cut  back  on  medications  due  to  high 
prescription  cost.  Inadequate  prescription 
coverage and out of pocket expenses is one of the 
strongest predictors of their medication adherence 
problems. 
Market  structure  and  subsequent  market 
segmentation  provide  a  basis  for  prescription 
agent pricing policies leading to wide variation in 
prices of drugs. In the absence of information on 
comparative drug prices and quality, it is difficult 
for  doctors  to  prescribe  the  most  economical 
prescription. 
There  is  a  need  for  concerted  action  from 
regulatory  authorities,  doctors,  pharmacists  and 
general public at large to address this issue of oral 
antidiabetic drugs price variation. At the hospital 
level authorities and concerned committees have 
to frame policies on these aspects. The situation 
can be improved by incorporating an analysis of 
prescription costs in the medical curriculum and 
by  providing  updated  and  complete  information 
regarding bioequivalence, quality and cost of the 
pharmaceutical  preparation  to  the  doctors. 
Wherever  possible  a  cheaper  brand  should  be 
prescribed  because  the  superiority  of  any 
particular  brand  over  the others  has  never  been 
proved  scientifically.  Currently,  very  few 
medicines  are  under  drug  prices  control 
order
16. Hence it is desired that the Government 
should bring all lifesaving and essential medicines 
under price control. 
 
CONCLUSION 
 
The  average  percentage  price  variation  of 
different brands of the same drug manufactured in 
India is very wide. So it is recommended that the 
appraisal  and  management  of  marketing  drugs 
should  be  directed  toward  maximizing  the 
benefits  of  therapy  and  minimizing  negative 
personal and economic consequences. 
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